NCT06112678View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

February 19, 2024

Study Completion Date

March 18, 2024

Conditions
HypertensionDyslipidemias
Interventions
DRUG

CKD-348(6)

QD, PO

DRUG

CKD-828, D097, D337

QD, PO

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY